{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T14:54:57Z","timestamp":1777992897956,"version":"3.51.4"},"reference-count":43,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2014,2,1]],"date-time":"2014-02-01T00:00:00Z","timestamp":1391212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1016\/j.semarthrit.2013.08.001","type":"journal-article","created":{"date-parts":[[2013,11,21]],"date-time":"2013-11-21T06:11:13Z","timestamp":1385014273000},"page":"458-469","source":"Crossref","is-referenced-by-count":79,"title":["Tocilizumab in rheumatoid arthritis: A meta-analysis of efficacy and selected clinical conundrums"],"prefix":"10.1016","volume":"43","author":[{"given":"Geraldine","family":"Navarro","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Taroumian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nashla","family":"Barroso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lewei","family":"Duan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Furst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.semarthrit.2013.08.001_bib1","first-page":"328","article-title":"Guidelines. ACoRSoRA. Guidelines for the management of rheumatoid arthritis","volume":"46","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2013.08.001_bib2","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1136\/ard.2007.083188","article-title":"Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials","volume":"68","author":"Salliot","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2013.08.001_bib3","first-page":"2109","article-title":"Safety and efficacy of rituximab in patients with rheumatoid arthritis refractory to disease modifying antirheumatic drugs and anti-tumor necrosis factor-alpha treatment","volume":"32","author":"Higashida","year":"2005","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2013.08.001_bib4","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.berh.2007.05.007","article-title":"Extra-articular manifestations and complications of rheumatoid arthritis","volume":"21","author":"Young","year":"2007","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2013.08.001_bib5","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1038\/clpt.2009.313","article-title":"Interleukin-6 as a therapeutic target in candidate inflammatory diseases","volume":"87","author":"Nishimoto","year":"2010","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.semarthrit.2013.08.001_bib6","first-page":"302","article-title":"Tocilizumab\u2014a new step in rheumatoid arthritis treatment","volume":"35","author":"Brand\u00e3o","year":"2010","journal-title":"Acta Reumatol Port"},{"key":"10.1016\/j.semarthrit.2013.08.001_bib7","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1111\/j.1742-1241.2010.02612.x","article-title":"Tocilizumab: is there life beyond anti-TNF blockade?","volume":"65","author":"Alves","year":"2011","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.semarthrit.2013.08.001_bib8","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.berh.2012.01.001","article-title":"Tocilizumab\u2014a novel therapy for non-organ-specific autoimmune diseases","volume":"26","author":"Kaly","year":"2012","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2013.08.001_bib9","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1186\/1478-6354-13-S1-S5","article-title":"Advances in rheumatology: new targeted therapeutics","volume":"13","author":"Tak","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2013.08.001_bib10","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1002\/art.27740","article-title":"Interleukin-6 receptor inhibition with tocilizumab and attainment of disease remission in rheumatoid arthritis: the role of acute-phase reactants","volume":"63","author":"Smolen","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2013.08.001_bib11","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1248\/bpb.30.2001","article-title":"Recent advances in immunopathophysiology of interleukin-6: an innovative therapeutic drug, tocilizumab (recombinant humanized anti-human interleukin-6 receptor antibody), unveils the mysterious etiology of immune-mediated inflammatory diseases","volume":"30","author":"Ohsugi","year":"2007","journal-title":"Biol Pharm Bull"},{"key":"10.1016\/j.semarthrit.2013.08.001_bib12","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/art.1780380602","article-title":"American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis","volume":"38","author":"Felson","year":"1995","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2013.08.001_bib13","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.semarthrit.2013.08.001_bib14","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3109\/s10165-008-0125-1","volume":"19","author":"Nishimoto","year":"2009","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.semarthrit.2013.08.001_bib15","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/S0140-6736(08)60453-5","article-title":"Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial","volume":"371","author":"Smolen","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.semarthrit.2013.08.001_bib16","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1136\/ard.2008.105197","article-title":"Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study","volume":"69","author":"Jones","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2013.08.001_bib17","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1136\/ard.2008.092932","article-title":"IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial","volume":"67","author":"Emery","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2013.08.001_bib18","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1002\/art.30158","volume":"63","author":"Kremer","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2013.08.001_bib19","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.1002\/art.23940","volume":"58","author":"Genovese","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2013.08.001_bib20","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1136\/ard.2010.148700","article-title":"Efficacy of tocilizumab in patients with moderate to severe active rheumatoid arthritis and a previous inadequate response to disease-modifying antirheumatic drugs: the ROSE study","volume":"71","author":"Yazici","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2013.08.001_bib21","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1002\/art.22033","article-title":"Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate","volume":"54","author":"Maini","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2013.08.001_bib22","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1136\/annrheumdis-2011-201282","article-title":"Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY)","volume":"72","author":"Dougados","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"9877","key":"10.1016\/j.semarthrit.2013.08.001_bib23","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(13)60250-0","article-title":"Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial","volume":"381","author":"Gabay","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.semarthrit.2013.08.001_bib24","doi-asserted-by":"crossref","first-page":"R141","DOI":"10.1186\/ar3455","article-title":"Integrated safety in tocilizumab clinical trials","volume":"13","author":"Schiff","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2013.08.001_bib25","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1136\/ard.2006.068064","article-title":"Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab","volume":"66","author":"Nishimoto","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2013.08.001_bib26","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1016\/S0140-6736(12)60027-0","article-title":"Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial","volume":"379","author":"van Vollenhoven","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.semarthrit.2013.08.001_bib27","unstructured":"US food and drug administration. Code of federal regulations. Title 21. [cited 2012 July 30]. Volume 5. Available from: http:\/\/www.accessdata.fda.gov."},{"key":"10.1016\/j.semarthrit.2013.08.001_bib28","series-title":"Hepatotoxicity, The Adverse Effects of Drugs and Other Chemicals on the Liver","article-title":"Drug-induced liver disease","author":"Zimmerman","year":"1978"},{"key":"10.1016\/j.semarthrit.2013.08.001_bib29","first-page":"S785","article-title":"Concomitant use of statins in tocilizumab-treated patients with rheumatoid arthritis with elevated low density\u00adlipoprotein\u00adcholesterol: analysis of five phase 3 clinical trials","author":"Genovese","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2013.08.001_bib30","article-title":"Open-label tofacitinib and double-blind atorvastatin in rheumatoid arthritis patients: a randomised study","author":"McInnes","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2013.08.001_bib31","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1080\/03009740802363776","article-title":"Changes in disease activity, cytokine production, and proliferation of peripheral blood mononuclear cells in patients with rheumatoid arthritis after simvastatin treatment","volume":"38","author":"Shirinsky","year":"2009","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.semarthrit.2013.08.001_bib32","first-page":"1459","article-title":"Effects of high-dose atorvastatin on antiinflammatory properties of high density lipoprotein in patients with rheumatoid arthritis: a pilot study","volume":"34","author":"Charles-Schoeman","year":"2007","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2013.08.001_bib33","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jacl.2010.02.005","article-title":"Atherogenic index of plasma (log10 triglyceride\/high-density lipoprotein-cholesterol) predicts high blood pressure, diabetes, and vascular events","volume":"4","author":"Onat","year":"2010","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.semarthrit.2013.08.001_bib34","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1194\/jlr.P011668","article-title":"Cholesterol esterification and atherogenic index of plasma correlate with lipoprotein size and findings on coronary angiography","volume":"52","author":"Dobi\u00e1sov\u00e1","year":"2011","journal-title":"J Lipid Res"},{"key":"10.1016\/j.semarthrit.2013.08.001_bib35","first-page":"1441","article-title":"Lipid and inflammation parameters: a translational, randomized placebo-controlled study to evaluate effects of tocilizumab: the MEASURE study","author":"McInnes","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2013.08.001_bib36","first-page":"S783","article-title":"Relationship between patient characteristics and the development of serious infections in patients receiving tocilizumab: results from long-term extension studies with a follow up duration of 1.5 years","author":"Kremer","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"22","key":"10.1016\/j.semarthrit.2013.08.001_bib37","doi-asserted-by":"crossref","first-page":"5652","DOI":"10.1002\/cncr.27615","article-title":"The cancer survival query system: making survival estimates from the surveillance, epidemiology, and end results program more timely and relevant for recently diagnosed patients","volume":"118","author":"Feuer","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.semarthrit.2013.08.001_bib38","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1038\/sj.bjc.6604935","article-title":"Risks of myeloid malignancies in patients with autoimmune conditions","volume":"100","author":"Anderson","year":"2009","journal-title":"Br J Cancer"},{"key":"10.1016\/j.semarthrit.2013.08.001_bib39","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/S0049-0172(99)80026-2","article-title":"The incidence of cancer associated with the treatment of rheumatoid arthritis","volume":"29","author":"Beauparlant","year":"1999","journal-title":"Semin Arthritis Rheum"},{"issue":"suppl 9","key":"10.1016\/j.semarthrit.2013.08.001_bib40","first-page":"784","article-title":"Safety of tocilizumab in patients with rheumatoid arthritis: pooled analysis of five phase 3 clinical trials","volume":"54","author":"Smolen","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"suppl 10","key":"10.1016\/j.semarthrit.2013.08.001_bib41","first-page":"1613","article-title":"Gastrointestinal safety in patients with rheumatoid arthritis treated with tocilizumab: data from Roche clinical trials","volume":"60","author":"Van Vollenhoven","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2013.08.001_bib42","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.2165\/11596240-000000000-00000","article-title":"Rheumatoid arthritis and pregnancy: safety considerations in pharmacological management","volume":"71","author":"Makol","year":"2011","journal-title":"Drugs"},{"key":"10.1016\/j.semarthrit.2013.08.001_bib43","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/S1297-319X(10)70001-4","article-title":"Tocilizumab: therapy and safety management","volume":"77","author":"Pham","year":"2010","journal-title":"Joint Bone Spine"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017213001686?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017213001686?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,10]],"date-time":"2020-08-10T08:48:54Z","timestamp":1597049334000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017213001686"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2]]},"references-count":43,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,2]]}},"alternative-id":["S0049017213001686"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2013.08.001","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2014,2]]}}}